HYDERGINE LC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydergine Lc, and what generic alternatives are available?
Hydergine Lc is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in HYDERGINE LC is ergoloid mesylates. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ergoloid mesylates profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDERGINE LC?
- What are the global sales for HYDERGINE LC?
- What is Average Wholesale Price for HYDERGINE LC?
Summary for HYDERGINE LC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | HYDERGINE LC at DailyMed |
US Patents and Regulatory Information for HYDERGINE LC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | HYDERGINE LC | ergoloid mesylates | CAPSULE;ORAL | 018706-001 | Jan 18, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HYDERGINE LC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | HYDERGINE LC | ergoloid mesylates | CAPSULE;ORAL | 018706-001 | Jan 18, 1983 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HYDERGINE LC
See the table below for patents covering HYDERGINE LC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 201046 | SOFT ELASTIC GELATINE CAPSULE DOSAGE FORMS CONTAINING SOLUTION OF ERGOT ALKALOID IN SOLVENT UNREACTIVE WITH CAPSULE SHELL | ⤷ Sign Up |
| Hong Kong | 53188 | PHARMACEUTICAL FORMULATIONS | ⤷ Sign Up |
| Sweden | 455161 | FORFARANDE FOR FRAMSTELLNING AV VETSKEFYLLDA MJUKA GELANTINKAPSLAR INNEHALLANDE ERGOTALKALOID SAMT KAPSLAR FRAMSTELLDA ENLIGT FORFARANDET | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
